3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Breast Neoplasms
40
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
20
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Endometrial Neoplasms
10
Pancreatic Neoplasms
9
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Neuroendocrine Tumors
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
Fulvestrant
5
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
Paclitaxel
2
Letrozole
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
Alpelisib
2
venetoclax
1
tivozanib
1
tipifarnib
1
sotorasib
1
pembrolizumab
1
olaparib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
ceralasertib
1
cemiplimab
1
capivasertib
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
olaparib
×
1 year
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled